Two biotech stocks worth watching who both own discovery platforms in addition to their trials are Dimerix (DXB) and Proteomics (PIQ).
Dimerix in particular is in phase 2 with interim results due soon plus final results due mid-year. Currently competing with Retrophin (NASDAQ) who has just completed phase 2 in a similar trial, but Retrophin are yet to discuss the forward plan with the FDA (unlike Dimerix who have met with the FDA).
2017 should be a big year for both these stocks. Fingers crossed for a biotech boom too which should see some stellar returns for outperforming stocks.
